Opioid rotation in clinical practice

Advances in Therapy

Volumn 29, Issue 10, 2012, Pages 849-863

  Nalamachu, Srinivas R ^a  

^a Clinical Research   (United States)

Author keywords

Abuse; Adverse events; Analgesia; Chronic pain; Opioids; Risk evaluation and mitigation strategies; Rotation; Switching

Indexed keywords

HYDROCODONE; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; OXYCODONE;

CHRONIC PAIN; CLINICAL PRACTICE; DRUG ABUSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENETIC ASSOCIATION; GENETIC DIFFERENCE; HUMAN; OPIATE ADDICTION; PAIN ASSESSMENT; QUALITATIVE RESEARCH; REVIEW; RISK REDUCTION; SEX DIFFERENCE; UNSPECIFIED SIDE EFFECT;

ANALGESICS, OPIOID; CHRONIC PAIN; DRUG SUBSTITUTION; PAIN MANAGEMENT; PAIN MEASUREMENT;

EID: 84872108234     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0051-7     Document Type: Review

References (94)

1. Portenoy RK, Lesage P. Management of cancer pain. Lancet. 1999;353:1695-700.
2. Wilson KE. Psychological implications of chronic pain. In: Raj P, ed. Practical Management of Pain. 3rd edition. St. Louis, MO: Mosby Inc; 2000:316-32.
3. World Health Organization. Cancer pain relief, with a guide to opioid availability. WHO Guideline. 2nd edition. Geneva, Switzerland: WHO. 1996:13-15.
4. Kalso E, Allan L, Dellemijn PL, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain. 2003;7:381-6.
5. Royal College of Anaesthetists, Royal College of General Practitioners, Royal College of Psychiatrists. Recommendations for the Appropriate Use of Opioids for Persistent Non-cancer Pain. London: The Pain Society; 2004. Available at: http://www.anaesthesiauk.com/documents/opioids-doc-2004.pdf. Accessed May 10 2012.
6. Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113-30.
7. Governale L. Outpatient Prescription Opioid Utilization in the US, Years 2000-2009. Presented July 22, 2010. Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM220950. pdf. Accessed May 10 2012.
8. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008;11:S63-88.
9. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64:465-74.
10. American Academy of Pain Medicine and the American Pain Society. The use of opioids for the treatment of chronic pain: a consensus statement. Clin J Pain. 1997;13:6-8.
11. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57:1331-46.
12. Argoff CE, Silvershein DI. A comparison of longand short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc. 2009;84:602-12.
13. Carson S, Thakurta S, Low A, Smith B, Chou R. Drug Class Review: Long-Acting Opioid Analgesics: Final Update 6 Report. Portland, OR: Oregon Health and Science University; 2011.
14. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32:304-15.
15. Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth Analg. 2000;90:933-7.
16. Grilo RM, Bertin P, Scotto di Fazano C, et al. Opioid rotation in the treatment of joint pain. A review of 67 cases. Joint Bone Spine. 2002;69:491-4.
17. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol. 2008;154:384-96.
18. Martini L, Whistler JL. The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol. 2007;17:556-64.
19. Mitra S. Opioid-induced hyperalgesia: pathophysiology and clinical implications. J Opioid Manag. 2008;4:123-30.
20. Fine PG. Clinical approaches to special issues related to opioid therapy. Semin Oncol Nursing. 2009;25:S20-8.
21. Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305:1315-21.
22. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2010;(11):CD004847.
23. Slatkin NE. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin. 2009;25:2133-50.
24. Muller-Busch HC, Lindena G, Tietze K, Woskanjan S. Opioid switch in palliative care, opioid choice by clinical need and opioid availability. Eur J Pain. 2005;9:571-9.
25. Pasternak GW. Molecular biology of opioid analgesia. J Pain Symptom Manage. 2005;29:S2-9.
26. Kieffer BL, Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol. 2002;66:285-306.
27. Kieffer BL. Opioids: first lessons from knockout mice. Trends Pharmacol Sci. 1999;20:19-26.
28. Matthes HW, Maldonado R, Simonin F, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the muopioidreceptor gene. Nature. 1996;383:819-23.
29. Pasternak GW. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci. 2001;22:67-70.
30. Kadiev E, Patel V, Rad P, et al. Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin Drug Metab Toxicol. 2008;4:77-91.
31. Crews JC, Sweeney NJ, Denson DD. Clinical efficacy of methadone in patients refractory to other p-opioid receptor agonist analgesics for management of terminal cancer pain case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics. Cancer. 1993;72:2266-72.
32. Chia YY, Chow LH, Hung CC, Liu K, Ger LP, Wang PN. Gender and pain upon movement are associated with the requirements for postoperative patient-controlled iv analgesia: a prospective survey of 2,298 Chinese patients. Can J Anaesth. 2002;49:249-55.
33. Sidebotham D, Dijkhuizen MRJ, Schug SA. The safety and utilization of patient-controlled anaesthesia. J Pain Symptom Manage. 1997;14:202-9.
34. De Kock M, Scholtes JL. Postoperative PCA in abdominal surgery. Analysis of 200 consecutive patients. Acta Anaesthesiol Belg. 1991;42:85-91.
35. Niesters M, Dahan A, Kest B, et al. Do sex differences exist in opioid analgesia? A systematic review and meta-analysis of human experimental and clinical studies. Pain. 2010;151:61-8.
36. Miller PL, Ernst AA. Sex differences in analgesia: a randomized trial of mu versus kappa opioid agonists. South Med J. 2004;97:35-41.
37. Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics. 2002;12:3-9.
38. Ross JR, Rutter D, Welsh K, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 2005;5:324-36.
39. Reyes-Gibby CC, Shete S, Rakvag T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007;130:25-30.
40. Rakvag TT, Klepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol-Omethyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain. 2005;116:73-8.
41. Ross JR, Riley J, Taegetmeyer AB, et al. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer. 2008;112:1390-403.
42. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240-3.
43. United States Food and Drug Administration. Approved Drug Products. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda. Accessed Jun 19 2012.
44. Kadian (morphine sulfate extended-release) capsules CII [package insert]. Morristown, NJ: Actavis Kadian; 2010.
45. Avinza (morphine sulfate extended-release capsules) CII [package insert]. Bristol, TN: King Pharmaceuticals, Inc.; 2011.
46. Cone EJ, Caplan YH, Moser F, Robert T, Black D. Evidence that morphine is metabolized to hydromorphone but not to oxymorphone. J Anal Toxicol. 2008;32:319-23.
47. OxyContin (oxycodone hydrochloride controlledrelease) tablets CII [package insert]. Stamford, CT: Purdue Pharma LP; 2011.
48. Opana ER (oxymorphone hydrochloride) extended-release tablets CII [package insert]. Chadds Ford, PA: Endo Pharmaceuticals; 2011.
49. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004;57:287-97.
50. Exalgo (hydromorphone hydrochloride) extended-release tablets CII [package insert]. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc.; 2010.
51. Duragesic (fentanyl transdermal system) CII [package insert]. Raritan, NJ: PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2009.
52. Oda Y, Kharasch ED. Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther. 2001;298:1021-32.
53. Ohtani M, Kotaki H, Sawada Y, Iga T. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther. 1995;272:505-10.
54. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11:S133-53.
55. Levorphanol tartrate tablets [package insert]. Columbus, OH: Roxane Laboratories, Inc.; 2011.
56. Ultram ER (tramadol HCl) extended-release tablets [package insert]. Raritan, NJ: PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2009.
57. Smith G, Stubbins MJ, Harries LW, Wolf CR. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica. 1998;28:1129-65.
58. Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980;17:102-5.
59. De Gregori M, Allegri M, De Gregori S, et al. How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments. Curr Drug Metab. 2010;11:276-82.
60. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996;392:30-4.
61. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther. 2007;81:429-44.
62. Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther. 1993;54:463-72.
63. Lotsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet. 2004;43:983-1013.
64. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004;32:447-54.
65. Susce MT, Murray-Carmichael E, de Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1356-8.
66. Foster A, Mobley E, Wang Z. Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract. 2007;7:352-6.
67. Parsells Kelly J, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Prevalence and characteristics of opioid use in the US adult population. Pain. 2008;138:507-13.
68. Bruera E, Sloan P, Mount B, Scott J, Suarez-Almazor M; Canadian Palliative Care Clinical Trials Group. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. J Clin Oncol. 1996;14:1713-17.
69. De Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity in terminal cancer patients. J Pain Symptom Manage. 1995;10:378-84.
70. Lee MA, Leng MEF, Tiernan EJJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med. 2001;15:26-34.
71. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84:613-24.
72. Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009;38:426-39.
73. Houde RW, Wallenstein SL, Rogers A. Clinical pharmacology of analgesics. 1. A method of assaying analgesic effect. Clin Pharmacol Ther. 1960;1:163-74.
74. Houde R, Wallenstein S, Beaver W. Evaluation of analgesics in patients with cancer pain. Clin Pharm. 1966;1:59-97.
75. Gammaitoni AR, Fine P, Alvarez N, McPherson ML, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain. 2003;19:286-97.
76. Brant JM. Opioid equianalgesic conversion: the right dose. Clin J Oncol Nurs. 2001;5:163-5.
77. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 1996;78:852-7.
78. Fine PG, Portenoy RK; for the Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing "best practices" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38:418-25.
79. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios of opioids: a critical review and proposals for long-term dosing. J Pain Symptom Manage. 2001;22:672-87.
80. Simpson KH. Individual choice of opioids and formulations: strategies to achieve the optimum for the patient. Clin Rheumatol. 2002;21:S5-8.
81. McNicol E, Horowicz-Mehler N, Fisk RA, et al; American Pain Society. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;5:231-56.
82. Morita T, Takigawa C, Onishi H, et al; Japan Pain, Rehabilitation, Palliative Medicine, and Psycho-Oncology (PRPP) Study Group. Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial. J Pain Symptom Manage. 2005;30:96-103.
83. Freye E, Anderson-Hillemacher A, Ritzdorf I, Levy JV. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Pract. 2007;7:123-9.
84. Narabayashi M, Saijo Y, Takenoshita S, et al. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial. Jpn J Clin Oncol. 2008;38:296-304.
85. Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med. 2008;9:595-612.
86. US Food and Drug Administration. Information for Healthcare Professionals: Methadone Hydrochloride. Rockville, MD: United States Food and Drug Administration. 2006. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm142841.htm. Accessed Aug 24 2012.
87. Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. Hyattsville, MD: United States Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2009. NCHS databrief no. 2. Available at: http://www.cdc.gov/nchs/data/databriefs/db22.htm. Accessed May 10 2012.
88. Katz NP, Birnbaum HG, Castor A. Volume of prescription opioids used nonmedically in the United States. J Pain Palliat Care Pharmacother. 2010;24:141-4.
89. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152:85-92.
90. US Department of Health and Human Services, US Food and Drug Administration. Prescription drug products containing acetaminophen; actions to reduce liver injury from unintentional overdose. Federal Register. 2011;76:2691-7.
91. Gilson AM, Maurer MA, Joranson DE. State medical board members' beliefs about pain, addiction, and diversion and abuse: a changing regulatory environment. J Pain. 2007;8:682-91.
92. Craig DS. The Food and Drug Administration risk evaluation and mitigation strategy. J Pain Palliat Care Pharmacother. 2010;24:145-8.
93. US Food and Drug Administration. FDA introduces new safety measures for extended-release and longacting opioid medications. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310870.htm. Accessed Jul 9 2012.
94. Jacox A, Carr DB, Payne R. New clinical practice guidelines for the management of pain in patients with cancer. N Engl J Med. 1994;330:651-5.